Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 27, 2026

Avian Influenza Surveillance with FTA Cards: Field Methods, Biosafety, and Transportation Issues Solved
12:09

Avian Influenza Surveillance with FTA Cards: Field Methods, Biosafety, and Transportation Issues Solved

Published on: August 2, 2011

19.7K

[Waldenström macroglobulinaemia].

Laurence Simon1, Véronique Leblond1

  • 1Service d'hématologie clinique, groupe hospitalier La Pitié-Salpêtrière, Paris, France.

La Revue Du Praticien
|March 15, 2019
PubMed
Summary

Waldenström macroglobulinaemia (WM) is a rare B-cell cancer. Current treatments combine chemotherapy with anti-CD20 antibodies, but new drugs like Bruton tyrosine kinase (BTK) inhibitors offer improved options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

EClinicalMedicine·2026
Same author

Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia.

Leukemia·2025
Same author

Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Impact of renal and hepatic function on dihydropyrimidine dehydrogenase phenotype assessed by enzyme activity in peripheral blood mononuclear cells and uracilemia.

Clinical chemistry and laboratory medicine·2025
Same author

Phenotypic Profile of Waldenström Macroglobulinaemia B-Cells: Establishment of a Diagnosis Scoring System and Clinico-Biological Correlations.

Journal of cellular and molecular medicine·2025
Same author

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.

Blood advances·2024

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Waldenström macroglobulinaemia (WM) is a rare, indolent B-cell lymphoproliferative disorder.
  • Characterized by bone marrow involvement and monoclonal IgM production.
  • Symptoms arise from cytopenias, tumor burden, or IgM-related complications.

Purpose of the Study:

  • To provide an overview of Waldenström macroglobulinaemia.
  • To discuss current and emerging treatment strategies.
  • To highlight the role of genetic mutations and novel therapeutics.

Main Methods:

  • Review of existing literature on WM.
  • Analysis of diagnostic criteria and prognostic factors.
  • Evaluation of current therapeutic regimens and investigational drugs.

Main Results:

  • The majority of WM cases harbor somatic mutations in the MYD88 gene.
  • Standard first-line treatment involves anti-CD20 antibody-based regimens with chemotherapy (e.g., Rituximab, cyclophosphamide, dexamethasone).
  • Emerging therapies, including Bruton tyrosine kinase (BTK) inhibitors, show significant promise for relapsed/refractory disease and first-line treatment.

Conclusions:

  • Treatment decisions for WM are individualized based on patient factors and disease status.
  • Novel agents, particularly BTK inhibitors, are expanding therapeutic options.
  • Ongoing research is crucial for further improving outcomes in WM.
Keywords:
Waldenström disease

Related Experiment Videos

Last Updated: Jan 27, 2026

Avian Influenza Surveillance with FTA Cards: Field Methods, Biosafety, and Transportation Issues Solved
12:09

Avian Influenza Surveillance with FTA Cards: Field Methods, Biosafety, and Transportation Issues Solved

Published on: August 2, 2011

19.7K